Abstract
Hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), Epstein-Barr virus (EBV), human T-cell lymphotropic virus type 1 (HTLV-1), Kaposi’s sarcoma-associated herpesvirus (KSHV), and Merkel cell polyomavirus (MCV) contribute to about 10–15% global burden of human cancers. Conventional chemotherapy or molecular target therapies have been used to treat virus-associated cancers. However, a more proactive approach would be the use of antiviral treatment to suppress or eliminate viral infections to prevent the occurrence of cancer in the first place. Antiviral treatments against chronic HBV and HCV infection have achieved this goal, with significant reduction in the incidence of hepatocellular carcinoma in treated patients. Antiviral treatments for EBV, KSHV, and HTLV-1 had limited success in treating refractory EBV-associated lymphoma and post-transplant lymphoproliferative disorder, KSHV-associated Kaposi’s sarcoma in AIDS patients, and HTLV-1-associated acute, chronic, and smoldering subtypes of adult T-cell lymphoma, respectively. Therapeutic HPV vaccine and RNA interference-based therapies for treating HPV-associated infection or cervical cancers also showed some encouraging results. Taken together, antiviral therapies have yielded promising results in cancer prevention and treatment. More large-scale studies in a real-world setting are necessary to confirm the efficacy of antiviral therapy. Further investigation for more effective and convenient antiviral regimens warrants more attention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
AASLD-IDSA HCV Guidance Panel (2018) Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 67(10):1477–1492. https://doi.org/10.1093/cid/ciy585
Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour J-F, Forns X (2018) Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. J Hepatol 69(3):603–607. https://doi.org/10.1016/j.jhep.2018.05.039
ANRS collaborative study group on hepatocellular carcinoma (2016) Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 65(4):734–740. https://doi.org/10.1016/j.jhep.2016.05.045
Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O (2010) Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28(27):4177–4183. https://doi.org/10.1200/JCO.2010.28.0669
Benitez-Hess ML, Reyes-Gutierrez P, Alvarez-Salas LM (2011) Inhibition of human papillomavirus expression using DNAzymes. Methods Mol Biol 764:317–335. https://doi.org/10.1007/978-1-61779-188-8_21
Besson C, Panelatti G, Delaunay C, Gonin C, Brebion A, Hermine O, Plumelle Y (2002) Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma 43(12):2275–2279
Bharti AC, Singh T, Bhat A, Pande D, Jadli M (2018) Therapeutic startegies for human papillomavirus infection and associated cancers. Front Biosci (Elite Ed) 10:15–73. https://doi.org/10.2741/e808
Biver-Dalle C, Nguyen T, Touze A, Saccomani C, Penz S, Cunat-Peultier S, Riou-Gotta MO, Humbert P, Coursaget P, Aubin F (2011) Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus. Acta Oncol 50(3):479–480. https://doi.org/10.3109/0284186X.2010.512924
Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200(12):1623–1633. https://doi.org/10.1084/jem.20040890
Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9(9):510–519. https://doi.org/10.1038/nrclinonc.2012.111
Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32(8):798–808. https://doi.org/10.1200/JCO.2013.51.5304
Bonanni P, Bechini A, Donato R, Capei R, Sacco C, Levi M, Boccalini S (2015) Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines 3(1):3–12. https://doi.org/10.1177/2051013614557476
Borges ÁH (2017) Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS 12(1):12–19. https://doi.org/10.1097/COH.0000000000000334
Borges AH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R, Group ISS (2016) Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. Clin Infect Dis 63(12):1668–1676. https://doi.org/10.1093/cid/ciw621
Boulet GA, Horvath CA, Berghmans S, Bogers J (2008) Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 17(4):810–817. https://doi.org/10.1158/1055-9965.EPI-07-2865
Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, Copas A, Boshoff C (2004) Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18(3):485–493. https://doi.org/10.1097/00002030-200402200-00015
Bower M, Palmieri C, Dhillon T (2006) AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 19(1):14–19. https://doi.org/10.1097/01.qco.0000200295.30285.13
Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S, Nelson M (2014) Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol 32(5):409–414. https://doi.org/10.1200/JCO.2013.51.6757
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL (2008) Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135(2):459–467. https://doi.org/10.1053/j.gastro.2008.05.031
Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P, GS-US-320-0108 Investigators (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):196–206. https://doi.org/10.1016/S2468-1253(16)30107-8
Bzhalava D, Eklund C, Dillner J (2015) International standardization and classification of human papillomavirus types. Virology 476:341–344. https://doi.org/10.1016/j.virol.2014.12.028
Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C (2019) Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 71(2):265–273. https://doi.org/10.1016/j.jhep.2019.03.027
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Craxì A, Di Marco V, Cammà C, Calvaruso V, Petta S, Cabbibbo G, Colletti P, Mazzola G, Cascio A, Montalto G, Licata A, Giannitrapani L, Prestileo T, Di Lorenzo F, Sanfilippo A, Ficalora A, Madonia S, Tinè F, Malizia G, Latteri F, Maida M, Cartabellotta F, Vassallo R, Cacciola I, Caccamo G, Maimone S, Saitta C, Squadrito G, Raimondo G, Mondello L, Smedile A, D’Andrea S, Bertino G, Ardiri AL, Frazzetto E, Rigano G, Montineri A, Larocca LN, Cacopardo B, Benanti F, Russello M, Benigno R, Bellia A, Iacobello C, Davì A, Di Rosolini MA, Digiacomo A, Fuduli G, Scifo G, Distefano M, Portelli V, Savalli F, Scalici I, Gioia G, Magro A, Alaimo G, Alinovi MR, Salvo A, Averna A, Lomonaco F, Guarneri L, Maffeo F, Falzone E, Pulvirenti F (2018) Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 155(2):411–421.e414. https://doi.org/10.1053/j.gastro.2018.04.008
Cammà C, Giunta M, Andreone P, Craxi A (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34(4):593–602. https://doi.org/10.1016/S0168-8278(01)00005-8
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord (2016) Changing incidence and risk factors for Kaposi sarcoma by time since starting antiretroviral therapy: collaborative analysis of 21 European cohort studies. Clin Infect Dis 63(10):1373–1379. https://doi.org/10.1093/cid/ciw562
Carter JJ, Paulson KG, Wipf GC, Miranda D, Madeleine MM, Johnson LG, Lemos BD, Lee S, Warcola AH, Iyer JG, Nghiem P, Galloway DA (2009) Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 101(21):1510–1522. https://doi.org/10.1093/jnci/djp332
Casper C (2011) The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 62:157–170. https://doi.org/10.1146/annurev-med-050409-103711
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II (2018) Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res 5:46–58. https://doi.org/10.1016/j.pvr.2017.12.006
Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K, Gs-Us-Investigators (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):185–195. https://doi.org/10.1016/S2468-1253(16)30024-3
Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS, Taiwan Hepatoma Study Group (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101(19):1348–1355. https://doi.org/10.1093/jnci/djp288
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, B. EHoLD AI463022 Study Group (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001–1010. https://doi.org/10.1056/NEJMoa051285
Chen CJ, Yang HI, Iloeje UH (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49(5 Suppl):S72–84. https://doi.org/10.1002/hep.22884
Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, Lai MS, Chen CJ (2015) Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology 61(4):1154–1162. https://doi.org/10.1002/hep.27630
Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW, Ng MH (2001) Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94(1):73–80. https://doi.org/10.1002/ijc.1430
Clark KT, Trimble CL (2020) Current status of therapeutic HPV vaccines. Gynecol Oncol 156(2):503–510. https://doi.org/10.1016/j.ygyno.2019.12.017
Coen N, Duraffour S, Snoeck R, Andrei G (2014) KSHV targeted therapy: an update on inhibitors of viral lytic replication. Viruses 6(11):4731–4759. https://doi.org/10.3390/v6114731
Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23(35):8942–8949. https://doi.org/10.1200/JCO.2005.02.6195
Dasari V, Sinha D, Neller MA, Smith C, Khanna R (2019) Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development. Expert Rev Vaccines 18(5):457–474. https://doi.org/10.1080/14760584.2019.1605906
Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A (2004) Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40(4):883–891. https://doi.org/10.1002/hep.20381
Dienstag JL (2009) Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49(5 Suppl):S112–121. https://doi.org/10.1002/hep.22920
Drolet M, Benard E, Perez N, Brisson M, HPV Vaccination Impact Study Group (2019) Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 394(10197):497–509. https://doi.org/10.1016/S0140-6736(19)30298-3
El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(6):1264–1273 e1261. https://doi.org/10.1053/j.gastro.2011.12.061
Etoh KI, Yamaguchi K, Tokudome S, Watanabe T, Okayama A, Stuver S, Mueller N, Takatsuki K, Matsuoka M (1999) Rapid quantification of HTLV-1 provirus load: detection of monoclonal proliferation of HTLV-1-infected cells among blood donors. Int J Cancer 81(6):859–864
European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370–398. https://doi.org/10.1016/j.jhep.2017.03.021
European Association for the Study of the Liver (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026
Faller DV, Mentzer SJ, Perrine SP (2001) Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 13(5):360–367. https://doi.org/10.1097/00001622-200109000-00008
Fang CT, Chen PJ, Chen MY, Hung CC, Chang SC, Chang AL, Chen DS (2003) Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 39(6):1028–1035. https://doi.org/10.1016/s0168-8278(03)00416-1
Feld JJ, Wong DK, Heathcote EJ (2009) Endpoints of therapy in chronic hepatitis B. Hepatology 49(5 Suppl):S96–S102. https://doi.org/10.1002/hep.22977
Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866):1096–1100. https://doi.org/10.1126/science.1152586
Fryer JF, Heath AB, Wilkinson DE, Minor PD (2016) A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques. Biologicals 44(5):423–433. https://doi.org/10.1016/j.biologicals.2016.04.010
Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, Oka S, Cheng A, Garner W, Fordyce M, Das M, McCallister S, GS-US-292-1249 Study Investigators (2016) Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J Acquir Immune Defic Syndr 73(3):294–298. https://doi.org/10.1097/QAI.0000000000001069
Gantt S, Casper C (2011) Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 24(4):295–301. https://doi.org/10.1097/QCO.0b013e3283486d04
Gessain A, Cassar O (2012) Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3:388. https://doi.org/10.3389/fmicb.2012.00388
Ghosh SK, Perrine SP, Faller DV (2012) Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies. Adv Virol 2012:509296. https://doi.org/10.1155/2012/509296
Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332(26):1744–1748. https://doi.org/10.1056/NEJM199506293322603
Global Burden of Disease Liver Cancer Collaboration (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 3(12):1683–1691. https://doi.org/10.1001/jamaoncol.2017.3055
Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC, Carneiro-Proietti AB (2010) Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 23(3):577–589. https://doi.org/10.1128/CMR.00063-09
Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Rodriguez AC, Burk RD (2007) High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 121(12):2787–2793. https://doi.org/10.1002/ijc.23012
Gustafsson Å, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk todevelop posttransplant llymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95(3):807–814
Hawkins C, Christian B, Ye JT, Nagu T, Aris E, Chalamilla G, Spiegelman D, Mugusi F, Mehta S, Fawzi W (2013) Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 27(6):919–927. https://doi.org/10.1097/QAD.0b013e32835cb9c8
He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ (2020) Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 51(1):34–52. https://doi.org/10.1111/apt.15598
Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, Bazarbachi A (1995) Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332(26):1749–1751
Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A, French ATL therapy group (2002) A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 3(6):276–282. https://doi.org/10.1038/sj.thj.6200195
Hermine O, Dombret H, Poupon J, Arnulf B, Lefrère F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, Degos L, Varet B, de Thé H, Bazarbachi A (2004) Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 5(2):130–134. https://doi.org/10.1038/sj.thj.6200374
Hermine O, Ramos JC, Tobinai K (2018) A review of new findings in adult T-cell leukemia–lymphoma: A focus on current and emerging treatment strategies. Adv Ther 35(2):135–152. https://doi.org/10.1007/s12325-018-0658-4
Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5):925–935. https://doi.org/10.1182/blood-2009-08-239186
Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, Kumaran T, Ardeshna KM, Pagliuca A, Taylor GP, Fields PA (2011) Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol 29(35):4696–4701. https://doi.org/10.1200/JCO.2011.35.5578
Hodson A, Laydon DJ, Bain BJ, Fields PA, Taylor GP (2013) Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma. Haematologica 98(3):385. https://doi.org/10.3324/haematol.2012.069476
Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8(5):257–264. https://doi.org/10.1038/nrgastro.2011.49
Huang AJ, Nunez M (2015) Outcomes in HIV/HBV-coinfected patients in the tenofovir era are greatly affected by immune suppression. J Int Assoc Provid AIDS Care 14(4):360–368. https://doi.org/10.1177/2325957415586258
Ioannou GN, Green PK, Berry K (2018) HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 68(1):25–32. https://doi.org/10.1016/j.jhep.2017.08.030
Ishitsuka K, Tamura K (2014) Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 15(11):e517–526. https://doi.org/10.1016/S1470-2045(14)70202-5
Israel BF, Kenney SC (2003) Virally targeted therapies for EBV-associated malignancies. Oncogene 22(33):5122–5130. https://doi.org/10.1038/sj.onc.1206548
Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K (2010) Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116(8):1211–1219. https://doi.org/10.1182/blood-2009-12-257410
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW, HBV 99-01 Study Group, Rotterdam Foundation for Liver Research (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454):123–129. https://doi.org/10.1016/S0140-6736(05)17701-0
Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH (2019) Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatol 71(3):473–485. https://doi.org/10.1016/j.jhep.2019.04.017
Jiang XW, Ye JZ, Li YT, Li LJ (2018) Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: a systematic review and meta-analysis. World J Gastroenterol 24(28):3181–3191. https://doi.org/10.3748/wjg.v24.i28.3181
Jones M, Nunez M (2011) HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS 6(6):546–552. https://doi.org/10.1097/COH.0b013e32834bcbd9
Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr (2008) Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 111(2):356–364. https://doi.org/10.1016/j.ygyno.2008.06.033
Josefsson AM, Magnusson PKE, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB (2000) Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355(9222):2189–2193. https://doi.org/10.1016/S0140-6736(00)02401-6
Jung HS, Erkin OC, Kwon MJ, Kim SH, Jung JI, Oh Y-K, Her SW, Ju W, Choi Y-L, Song SY, Kim JK, Kim YD, Shim GY, Shin YK (2012) The synergistic therapeutic effect of cisplatin with human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer 130(8):1925–1936. https://doi.org/10.1002/ijc.26197
Jung HS, Rajasekaran N, Ju W, Shin YK (2015) Human papillomavirus: current and future RNAi therapeutic strategies for cervical cancer. J Clin Med 4(5):1126–1155. https://doi.org/10.3390/jcm4051126
Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar MM, Shirdel A, Rastin M, Rafatpanah H, Tarhini M, Zalloua PA, Hermine O, Farid R, Bazarbachi A (2007) Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma 48(2):330–336. https://doi.org/10.1080/10428190601071717
Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rezaee SA, Yazdi MT, Shirdel A, de Thé H, Hermine O, Farid R, Bazarbachi A (2009) Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 113(26):6528–6532. https://doi.org/10.1182/blood-2009-03-211821
Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5(3):e1000363. https://doi.org/10.1371/journal.ppat.1000363
Kim WR, Benson JT, Hindman A, Brosgart C, Fortner-Burton C (2007) Decline in the need for liver transploantation for end stage liver disease secondary to hepatitis B in the US [Abstract]. Hepatology 46(Suppl):238A
Kimura H, Kwong YL (2019) EBV viral loads in diagnosis, monitoring, and response assessment. Front Oncol 9:62. https://doi.org/10.3389/fonc.2019.00062
Kimura H, Ito Y, Suzuki R, Nishiyama Y (2008) Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 18(5):305–319. https://doi.org/10.1002/rmv.582
Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H (2017) Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 89(3):476–483. https://doi.org/10.1002/jmv.24663
Koivusalo R, Krausz E, Helenius H, Hietanen S (2005) Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68(2):372–382. https://doi.org/10.1124/mol.105.011189
Kowalkowski MA, Kramer JR, Richardson PR, Suteria I, Chiao EY (2015) Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection. Clin Infect Dis 60(9):1405–1414. https://doi.org/10.1093/cid/civ012
Krasagakis K, Kruger-Krasagakis S, Tzanakakis GN, Darivianaki K, Stathopoulos EN, Tosca AD (2008) Interferon-alpha inhibits proliferation and induces apoptosis of merkel cell carcinoma in vitro. Cancer Invest 26(6):562–568. https://doi.org/10.1080/07357900701816477
Kutok JL, Wang F (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1:375–404. https://doi.org/10.1146/annurev.pathol.1.110304.100209
Lacombe K, Rockstroh J (2012) HIV and viral hepatitis coinfections: advances and challenges. Gut 61(Suppl 1):i47–58. https://doi.org/10.1136/gutjnl-2012-302062
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe Study Group (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25):2576–2588. https://doi.org/10.1056/NEJMoa066422
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, B. EHoLD AI463027 Study Group (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354(10):1011–1020. https://doi.org/10.1056/NEJMoa051287
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682–2695. https://doi.org/10.1056/NEJMoa043470
Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Worns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M (2020) Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int 40(5):1032–1041. https://doi.org/10.1111/liv.14320
Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y (2018) Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. Cancer Sci 109(7):2101–2108. https://doi.org/10.1111/cas.13634
Liaw YF (2006) Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 11(6):669–679
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531. https://doi.org/10.1056/NEJMoa033364
Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS (2014) Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 63(3):506–514. https://doi.org/10.1136/gutjnl-2012-304370
Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ (2018) Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology 154(4):989–997. https://doi.org/10.1053/j.gastro.2017.11.011
Lok ASF, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K (2016) Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63(1):284–306. https://doi.org/10.1002/hep.28280
Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33(9):983–990. https://doi.org/10.1097/CJI.0b013e3181f3cbf4
Loyo M, Guerrero-Preston R, Brait M, Hoque MO, Chuang A, Kim MS, Sharma R, Liegeois NJ, Koch WM, Califano JA, Westra WH, Sidransky D (2010) Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer 126(12):2991–2996. https://doi.org/10.1002/ijc.24737
Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC (2012) Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 17(4):469–492. https://doi.org/10.1517/14728214.2012.744393
MacDonald M, You J (2017) Merkel cell polyomavirus: a new DNA virus associated with human cancer. In: Cai Q, Yuan Z, Lan K (eds) Infectious agents associated cancers: epidemiology and molecular biology. Springer, Singapore, pp 35–56. https://doi.org/10.1007/978-981-10-5765-6_4
Manns A, Miley WJ, Wilks RJ, Morgan OSC, Hanchard B, Wharfe G, Caranston B, Maloney W, Welles SL, Blattner WA, Waters D (1999) Quantitative proviral DNA and antibody levels in the natural histroy of HTLV-1 infection. J Infect Dis 180(5):1487–1493
Manthravadi S, Paleti S, Pandya P (2017) Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer 140(5):1042–1049. https://doi.org/10.1002/ijc.30521
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351(12):1206–1217. https://doi.org/10.1056/NEJMoa040431
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359(23):2442–2455. https://doi.org/10.1056/NEJMoa0802878
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S (2009) Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136(7):2169–2179 e2161–2164. https://doi.org/10.1053/j.gastro.2009.03.006
Masuzaki R, Yoshida H, Omata M (2010) Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology 78(Suppl 1):17–23. https://doi.org/10.1159/000315225
Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT (2001) Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 113(3):779–784. https://doi.org/10.1046/j.1365-2141.2001.02794.x
Merchante N, Rivero-Juarez A, Tellez F, Merino D, Rios-Villegas MJ, Villalobos M, Omar M, Rincon P, Rivero A, Perez-Perez M, Raffo M, Lopez-Montesinos I, Palacios R, Gomez-Vidal MA, Macias J, Pineda JA, on behalf of the HEPAVIR-Cirrhosis Study Group (2018) Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother 73(9):2435–2443. https://doi.org/10.1093/jac/dky234
Merchante N, Rodriguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, Garcia-Deltoro M, Rivero-Juarez A, Tellez F, Delgado-Fernandez M, Rios-Villegas MJ, Garcia MA, Vera-Mendez FJ, Ojeda-Burgos G, Lopez-Ruz MA, Metola L, Omar M, Aleman-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macias J, Pineda JA, on behalf of the GEHEP-002 Study Group (2018) Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS 32(11):1423–1430. https://doi.org/10.1097/QAD.0000000000001809
Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A (2011) Immunotherapy for EBV-associated malignancies. Int J Hematol 93(3):281–293. https://doi.org/10.1007/s12185-011-0782-2
Mesri EA, Cesarman E, Boshoff C (2010) Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer 10(10):707–719. https://doi.org/10.1038/nrc2888
Mommeja-Marin H, Mondou E, Blum MR, Rousseau F (2003) Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37(6):1309–1319. https://doi.org/10.1053/jhep.2003.50208
Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B (2009) Clinical course of classic Kaposi’s sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 23(4):534–538. https://doi.org/10.1097/QAD.0b013e3283262a8d
Moore PS, Chang Y (2010) Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 10(12):878–889. https://doi.org/10.1038/nrc2961
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158(5 Pt 1):329–337. https://doi.org/10.7326/0003-4819-158-5-201303050-00005
Mucke MM, Backus LI, Mucke VT, Coppola N, Preda CM, Yeh ML, Tang LSY, Belperio PS, Wilson EM, Yu ML, Zeuzem S, Herrmann E, Vermehren J (2018) Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 3(3):172–180. https://doi.org/10.1016/S2468-1253(18)30002-5
Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:296. https://doi.org/10.1186/1743-422X-7-296
Nakajima H, Takaishi M, Yamamoto M, Kamijima R, Kodama H, Tarutani M, Sano S (2009) Screening of the specific polyoma virus as diagnostic and prognostic tools for Merkel cell carcinoma. J Dermatol Sci 56(3):211–213. https://doi.org/10.1016/j.jdermsci.2009.07.013
Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22(8):937–945. https://doi.org/10.1097/QAD.0b013e3282ff6275
Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334(22):1422–1427. https://doi.org/10.1056/NEJM199605303342202
Okayama A, Stuver S, Matsuoka M, Ishizaki J, Tanaka G, Kubuki Y, Mueller N, Hsieh CC, Tachibana N, Tsubouchi H (2004) Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 110(4):621–625. https://doi.org/10.1002/ijc.20144
Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ (2001) Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 15(5):689–698. https://doi.org/10.1046/j.1365-2036.2001.00979.x
Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ (2008) Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 8(3):167–178. https://doi.org/10.1016/S1473-3099(07)70264-5
Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53(2):348–356. https://doi.org/10.1016/j.jhep.2010.02.035
Perrine SP, Hermine O, Small T, Suarez F, O’Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109(6):2571–2578. https://doi.org/10.1182/blood-2006-01-024703
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphcytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77(12):7514–7519
Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, McMillan NA (2005) RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 68(5):1311–1319. https://doi.org/10.1124/mol.105.014191
Qu LS, Chen H, Kuai XL, Xu ZF, Jin F, Zhou GX (2012) Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: a meta-analysis of randomized controlled trials. Hepatol Res 42(8):782–789. https://doi.org/10.1111/j.1872-034X.2012.00984.x
Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M (2009) Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS ONE 4(2):e4420. https://doi.org/10.1371/journal.pone.0004420
Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao J-H, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X (2018) Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 68(4):1298–1307. https://doi.org/10.1002/hep.30046
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M (2018) Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 Study. Clin Infect Dis 67(7):1010–1017. https://doi.org/10.1093/cid/ciy220
Roden RBS, Stern PL (2018) Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer 18(4):240–254. https://doi.org/10.1038/nrc.2018.13
Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345(8941):9–13. https://doi.org/10.1016/S0140-6736(95)91150-2
Rosales R, Lopez-Contreras M, Rosales C, Magallanes-Molina JR, Gonzalez-Vergara R, Arroyo-Cazarez JM, Ricardez-Arenas A, Del Follo-Valencia A, Padilla-Arriaga S, Guerrero MV, Pirez MA, Arellano-Fiore C, Villarreal F (2014) Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther 25(12):1035–1049. https://doi.org/10.1089/hum.2014.024
Sandmann L, Schulte B, Manns MP, Maasoumy B (2019) Treatment of chronic hepatitis C: efficacy side effects and complications. Visceral Med 35(3):161–170. https://doi.org/10.1159/000500963
Schrama D, Ugurel S, Becker JC (2012) Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol 24(2):141–149. https://doi.org/10.1097/CCO.0b013e32834fc9fe
Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X, Luo A, Zhou J, Xu G, Meng L, Lu Y, Ma D (2007) Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 106(2):299–304. https://doi.org/10.1016/j.ygyno.2007.04.039
Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK (2010) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8(2):192–199
Singal AK, Salameh H, Kuo YF, Fontana RJ (2013) Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 38(2):98–106. https://doi.org/10.1111/apt.12344
Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND (2019) Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north American cohort study. Gastroenterology 156(6):1683–1692.e1681. https://doi.org/10.1053/j.gastro.2019.01.027
Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, Kwong D, Khanna R (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72(5):1116. https://doi.org/10.1158/0008-5472.CAN-11-3399
Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, Li V, Tiu R, Smith D, Neller MA, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls J, Kwong D, Khanna R (2017) Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response. Oncoimmunology 6(2):e1273311. https://doi.org/10.1080/2162402X.2016.1273311
Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood 105(5):1898–1904. https://doi.org/10.1182/blood-2004-07-2975
Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH, C-TEAM study group and the Taiwan Liver Diseases Consortium (2016) Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 36(12):1755–1764. https://doi.org/10.1111/liv.13253
Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL (2008) Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28(9):1067–1077. https://doi.org/10.1111/j.1365-2036.2008.03816.x
Sunil M, Reid E, Lechowicz MJ (2010) Update on HHV-8-associated malignancies. Curr Infect Dis Rep 12(2):147–154. https://doi.org/10.1007/s11908-010-0092-5
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4):1560–1599. https://doi.org/10.1002/hep.29800
Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, Chang Y, Buck CB, Moore PS (2009) Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 125(6):1250–1256. https://doi.org/10.1002/ijc.24509
Toy M, Veldhuijzen IK, De Man RA, Richardus J, Schalm SW (2008) The potential impact of long-term nucleodise therapy on the mortality and morbidity of high viremic chronic hepatitis B [Abstract]. Hepatology 48(Suppl):717A
Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T (2009) Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27(3):453–459. https://doi.org/10.1200/JCO.2008.18.2428
Uldrick TS, Polizzotto MN, Aleman K, O’Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R (2011) High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 117(26):6977–6986. https://doi.org/10.1182/blood-2010-11-317610
van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39(3):804–810. https://doi.org/10.1002/hep.20128
Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gjaerde LK, Rockstroh J, Neau D, Bonnet F, Rauch A, Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort (2019) Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: relevance for screening strategies. J Hepatol 71(2):274–280. https://doi.org/10.1016/j.jhep.2019.03.032
Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ (2017) Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 67(6):1204–1212. https://doi.org/10.1016/j.jhep.2017.07.025
Wei L, Kao JH (2017) Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naive patients with chronic hepatitis B. Curr Med Res Opin 33(3):495–504. https://doi.org/10.1080/03007995.2016.1264932
WHO Global hepatitis report (2017) April, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 5 Feb 2020
Willmes C, Adam C, Alb M, Volkert L, Houben R, Becker JC, Schrama D (2012) Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens. Cancer Res 72(8):2120–2128. https://doi.org/10.1158/0008-5472.CAN-11-2651
Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL (2010) Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 32(9):1059–1068. https://doi.org/10.1111/j.1365-2036.2010.04447.x
Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7(1):11–22. https://doi.org/10.1038/nrc2050
Wyles D, Brau N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M, ASTRAL-5 Investigators (2017) Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis 65(1):6–12. https://doi.org/10.1093/cid/cix260
Xi LF, Hughes JP, Castle PE, Edelstein ZR, Wang C, Galloway DA, Koutsky LA, Kiviat NB, Schiffman M (2011) Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis 203(10):1425–1433. https://doi.org/10.1093/infdis/jir049
Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N (2009) Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 16(4):265–271. https://doi.org/10.1111/j.1365-2893.2009.01070.x
Yang A, Farmer E, Wu TC, Hung C-F (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23(1):75. https://doi.org/10.1186/s12929-016-0293-9
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y
Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, Dittmer DP, Kitahata MM, Mugavero MJ, Saag M, Moore RD, Mayer K, Mathews WC, Hunt PW, Rodriguez B, Eron JJ (2013) Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis 57(5):756–764. https://doi.org/10.1093/cid/cit369
Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS (2011) Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer 129(5):1254–1264. https://doi.org/10.1002/ijc.25767
Zhou J, Peng C, Li B, Wang F, Zhou C, Hong D, Ye F, Cheng X, Lu W, Xie X (2012) Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol Oncol 124(2):296–302. https://doi.org/10.1016/j.ygyno.2011.10.028
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shih, WL., Fang, CT., Chen, PJ. (2021). Chapter XX Antiviral Treatment and Cancer Control. In: Wu, TC., Chang, MH., Jeang, KT. (eds) Viruses and Human Cancer. Recent Results in Cancer Research, vol 217. Springer, Cham. https://doi.org/10.1007/978-3-030-57362-1_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-57362-1_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57361-4
Online ISBN: 978-3-030-57362-1
eBook Packages: MedicineMedicine (R0)